Finerenone to lower protein in urine for diabetes kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a once-daily pill called finerenone to see if it can reduce protein in the urine (a sign of kidney damage) in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and slow down disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with type 2 diabetes.
- You have kidney disease with moderate protein leakage (UACR between 30 and 2000 mg/g) and your eGFR (a kidney function measure) is at least 30.
- You must be taking the highest dose of an ACE inhibitor or ARB (kidney-protecting blood pressure medication) you can tolerate for at least 3 months.
- Your blood sugar control is good (hemoglobin A1c less than 8%) and your potassium level is no higher than 5.0.
- You do not have heart failure, recent heart or blood vessel events (like heart attack or stroke), or other serious medical conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This trial is testing a medication called finerenone to see how well it helps people with type 2 diabetes who also have chronic kidney disease. Researchers are looking at how the drug affects kidney function and related health factors.
This study looks at how the medication finerenone works in everyday medical practice for people with type 2 diabetes and certain stages of chronic kidney disease. It aims to see how safe and effective the treatment is outside of a clinical trial setting.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This observational study tracks how well finerenone (a kidney-protective medication) works in adults with type 2 diabetes and chronic kidney disease in Spain. Researchers will measure changes in kidney function and disease risk over time to better understand the medication's real-world benefits.
Hear when a new Albuminuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.